Regeneron PharmaceuticalsREGN
Recorded

Regeneron Pharmaceuticals Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration26 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Akash TewariAnalyst

All righty. Thanks, everyone. Good afternoon. Day two of our Jefferies Healthcare Conference. My name's Akash Tewari. I lead our pharma and biotech efforts on the research side for Jefferies. I have the pleasure of hosting the Regeneron management team. Why don't I hand it off to Chris for some intro remarks, and then Ryan for some compliance remarks, which are very important.

Ryan CroweSVP of Investor Relations and Strategic Analysis

Yeah, we'll start with the compliance remarks. I'll get those out of the way and let Chris say a couple opening remarks, and then we'll jump right to your questions. I'd like to remind you that remarks made today may include forward-looking statements about Regeneron, and each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements. A description of material risks and uncertainties can be found in Regeneron's SEC filings. Regeneron does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.

Christopher FenimoreCFO

Chris? Thanks, Ryan, and Akash, thanks for having us.

Christopher FenimoreCFO

It's a great conference, and we're very happy to be here. I think if you look at Regeneron for the third quarter, we came off a very strong commercial execution and performance. You saw $5.1 billion of revenue, basically, which was 36% year-over-year growth, and you saw non-GAAP EPS growth, where it was just over $20 per share, which was just about 70% year-over-year growth. That was largely driven by the commercial performance of our three largest growth drivers, each hitting record highs. If you look at EYLEA HD, it hit just about $700 million for the quarter. Libtayo, which is really, our commercial team has done a remarkable job in execution on Libtayo, annualizing at about $2.2 billion a year, and did about $550 million globally for the quarter. And then obviously, Dupixent. Dupixent continues to do remarkably well. It did about $6.5 billion globally for the quarter, about $5 billion in the U.S. alone.

Christopher FenimoreCFO

And one thing that we should not forget about in terms of the economics of the alliance is we repaid the development balance, which, when we first started repaying it, amounted to about $3 billion. We completely paid that off in the second quarter, so we saw the full benefit of the repayment of that development balance in the third quarter. We will obviously see that again in the fourth quarter, and then looking forward to 2027, we will also see the benefit of that in terms of comps for the first two quarters of 2027.

Christopher FenimoreCFO

On the pipeline front, and I am sure we will get to some of these questions as we talk to Akash Tewari here, is, we like to say at Regeneron, sometimes you only see the tip of the iceberg. We have focused a lot of time on our later-stage opportunities in the pipeline, but this time, on our third quarter call, we started to showcase some of our earlier-stage opportunities, which we plan on advancing rapidly, obviously as rapidly as we can, and I am sure we will talk about that. There is an opportunity in MASH with CIDEB. There is obviously an opportunity with ovarian cancer for our MUC16 bispecific, ubamatamab. Then the last one is an opportunity in POTS, which is postural orthostatic tachycardia syndrome, where we believe there is a significant unmet medical need there.

Christopher FenimoreCFO

With our R&D folks in place really working on these programs, our goal is to try and bring these therapies as well as others as fast as we can to meet those unmet medical needs.

Akash TewariAnalyst

Very helpful. Let us start a bit with really what is going on with EYLEA and the franchise. I cannot help but notice, I mean, the strength that we saw in EYLEA, if you look at Vabysmo, they also had a strong quarter. If you look at even some of the GA products, they had a strong quarter. You talk to Roche, they will tell you there has been a stabilization on the eye care market, and it is not necessarily as product-specific. It seems like it is more market-specific. Talk to us about the challenges that we have seen in the wet AMD market over the last couple years, and would you agree with that characterization that we have actually rebased in the U.S. and we are in a period of more commercial certainty?

Christopher FenimoreCFO

Yeah. So if you look at the market starting in the beginning of 2025, there was what we call affordability challenges out there, where patients that are on government-funded programs, in order to get assistance for their co-pays, need to seek that assistance from not-for-profit foundations. There was a challenge in availability of some of that co-pay assistance funding, and that really changed the dynamics of the branded market starting in 2025. What we are seeing now is a stabilization of that dynamic, where I do not want to make light of the fact that the affordability challenges still exist for patients, and that is something that we do not take lightly, and we are prepared to assist those patients, and we have a matching program that is in place, and we are looking for others to basically help those patients that are out there. But from an economic perspective, Akash Tewari, you are right.

Christopher FenimoreCFO

That piece of the market seems to have stabilized in terms of the impact of those patients that were put on an unbranded, basically Avastin product. What we can say is the demographics clearly demonstrate that we would expect the market to continue to grow overall, probably in the low single-digit range, where you've got just an aging of the population, then you've got those, unfortunately, challenged with facing diabetes and more diagnosis of the diabetic sort of retinal disease category. So, that's what we would expect, and we're optimistic about that growth going forward.

Akash TewariAnalyst

Very helpful. Just to hit on a finer point, because I find I'm personally surprised. It's not like people have stepped up to the plate on the matching program. So, it's not like the foundations have, quote-unquote, now the coffers are filled. No, we're not seeing that. But we have seen Eylea's use decline 5%-10% recently. So, there's something else going on. It's not foundations. So, talk to us about what's actually occurring, even if foundations aren't getting funded, that's allowing for the affordability issues we've seen with this class to get solved. Is it people getting insurance? Is it Medicare and Medicaid dual coverage? What's going on at the ground level?

Christopher FenimoreCFO

I think it's hard, Akash, to say specifically what's going on, but you're right. We have seen a little bit of the pressure from Eylea in terms of share backing off a little bit. What we have heard anecdotally, and again, this is purely anecdotal from feedback from the field, is that those patients that are on traditional Medicare Part B, some of them may have been out there securing what they call Medigap coverage to help with their copay assistance. It's really hard to say how much of that contributed to it. Or there could just be examples of patients that decided, based on the clinical benefit, that they were willing to fund some of the copays, assuming that they could afford it, but it's hard to say.

Akash TewariAnalyst

Okay, understood. Touching a bit on the prefilled syringe, and you talked about over the last couple of years, say, there's three unlocks we need to have to really get high dose to reach its potential. You've delivered on two of them. Seemingly, cat hair has stood in the way on the prefilled syringe getting approved. But talk to us a bit about your confidence. You still have a pending regulatory decision with the FDA. You've used the term optimistic. So, what is your confidence that we could hear back from the agency on your prefilled syringe going into 2027? When we think about how much that unlocks the market opportunity for high dose, what should we be thinking about in terms of, hey, now there's maybe 20% of our patients that have been waiting for a prefilled syringe formulation?

Christopher FenimoreCFO

The answer to your question is, we are still optimistic. I mean, that's the word that, as you described it, we used on our call, and we still continue to believe that we are optimistic in terms of achieving that approval by the end of the year. What I will say is, if you look at the performance of Eylea HD over the course of 2026, what we have seen is, as you've talked about, the unlocking of some of these enhancements to the competitive profile of the product really starting to come through. If you look at the retinal vein occlusion indication, that was somewhere in the neighborhood of basically 20% of the market that we were unable to tap into, and we are now seeing, now that physicians have the ability to use Eylea HD, that we're seeing strong performance in that market segment.

Christopher FenimoreCFO

The other aspect of the performance is reimbursement confidence. It was really important to the provider community that they had the ability to know that if they prescribed HD, that they were going to get reimbursed for those patients that were difficult to treat. The fact that we added every four-week dosing to the label definitely helped in that reimbursement confidence. As you look at the prefilled syringe and what we think that will mean in terms of going forward towards the end of the year and then obviously into 2027, yes, we believe there'll be some additional inflection. It's hard to say how meaningful that inflection will be. There are some examples, very, very limited, where some providers have said they will not adopt Eylea HD. That's really not that prevalent out there.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day